

Nuri Faruk Aykan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5015691/publications.pdf>

Version: 2024-02-01

48
papers

796
citations

623574

14
h-index

526166

27
g-index

48
all docs

48
docs citations

48
times ranked

1450
citing authors

#	ARTICLE	IF	CITATIONS
1	The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, , 1.	0.6	1
2	Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. <i>BMJ Open</i> , 2020, 10, e027665.	0.8	7
3	Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. <i>BMC Cancer</i> , 2020, 20, 259.	1.1	7
4	Objective response rate assessment in oncology: Current situation and future expectations. <i>World Journal of Clinical Oncology</i> , 2020, 11, 53-73.	0.9	49
5	Body Mass Index and Colorectal Cancer. , 2019, , .		0
6	Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 214-220.	0.6	15
7	Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers. <i>Tumori</i> , 2018, 104, 266-272.	0.6	1
8	Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. <i>Surgical Oncology</i> , 2018, 27, 485-489.	0.8	6
9	Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 787-797.	0.4	2
10	Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report. <i>World Journal of Radiology</i> , 2017, 9, 365-370.	0.5	3
11	Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 264-272.	0.6	2
12	Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 47-54.	0.6	15
13	Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma. <i>Clinical and Translational Oncology</i> , 2016, 18, 160-171.	1.2	26
14	Clinical significance of serum claudin-1 and claudin-7 levels in patients with colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1255-1267.	0.4	14
15	Red meat subtypes and colorectal cancer risk. <i>International Journal of Cancer</i> , 2015, 137, 1788-1788.	2.3	4
16	Red meat and colorectal cancer. <i>Oncology Reviews</i> , 2015, 9, 288.	0.8	105
17	Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 140-146.	2.5	14
18	Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62</i>	0.4	24

#	ARTICLE	IF	CITATIONS
19	Clinical significance of serum vascular cell adhesion molecule-1 (VCAM-1) in colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 550-550.	0.8	0
20	Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?. Journal of Clinical Oncology, 2015, 33, e14531-e14531.	0.8	0
21	Prognostic roles of serum NEDD9 levels in patients with gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15103-e15103.	0.8	0
22	Clinical significance of serum claudin-7 levels in patients with colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14533-e14533.	0.8	0
23	Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients. Tumor Biology, 2014, 35, 11871-11877.	0.8	8
24	Can Complementary ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?. Journal of Nuclear Medicine, 2014, 55, 1811-1817.	2.8	82
25	Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma. Tumor Biology, 2014, 35, 2729-2739.	0.8	6
26	Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2014, 32, 203-203.	0.8	0
27	The diagnostic, predictive, and prognostic role of serum cellular adhesion molecules (VCAM-1, EpCAM) levels in breast cancer patients.. Journal of Clinical Oncology, 2014, 32, e22001-e22001.	0.8	0
28	Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?. Medical Oncology, 2013, 30, 660.	1.2	13
29	Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clinical and Translational Oncology, 2013, 15, 403-408.	1.2	9
30	A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma. Journal of Gastrointestinal Oncology, 2011, 2, 19-26.	0.6	7
31	Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. Investigational New Drugs, 2008, 26, 567-572.	1.2	37
32	The role of UFT in advanced gastric cancer. Annals of Oncology, 2008, 19, 1045-1052.	0.6	10
33	XELOX Followed by XELIRI or the Reverse Sequence in Advanced Colorectal Cancer. Oncology, 2007, 73, 298-304.	0.9	7
34	Message-adjusted network (MAN) hypothesis in gastro-entero-pancreatic (GEP) endocrine system. Medical Hypotheses, 2007, 69, 571-574.	0.8	2
35	Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an experience of single institute. Medical Oncology, 2007, 24, 384-387.	1.2	0
36	Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread?. Melanoma Research, 2006, 16, 259-261.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 205-209.	0.6	46
38	Prognostic Features and Survival of Inoperable Hepatocellular Carcinoma in Turkish Patients With Cirrhosis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 489-493.	0.6	17
39	A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Annals of Oncology, 2003, 14, 1106-1114.	0.6	17
40	Colorectal Cancer in Young Patients: Characteristics and Outcome. Tohoku Journal of Experimental Medicine, 2003, 199, 85-93.	0.5	44
41	Adjuvant Intraperitoneal Chemotherapy With Cisplatin, Mitoxantrone, 5-Fluorouracil, and Calcium Folate in Patients With Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 619-624.	0.6	18
42	Prognostic Factors in Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 547-550.	0.6	93
43	Measurement of Serum CA 19-9 May Be More Valuable Than CEA in Prediction of Recurrence in Patients With Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 148-149.	0.6	13
44	Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. British Journal of Cancer, 2001, 84, 611-620.	2.9	22
45	The Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 53-57.	0.6	16
46	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer, 1998, 83, 2475-2480.	2.0	11
47	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer, 1998, 83, 2475-80.	2.0	8
48	The efficacy of a five-drug antiemetic combination during chemotherapy regimens containing cisplatin or cyclophosphamide-doxorubicin. Journal of Pain and Symptom Management, 1993, 8, 126-131.	0.6	2